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Background/aim: Alzheimer disease (AD) is characterized by the accumulation of senile plaques composed of amyloid β-peptide,
which is derived from β-amyloid precursor protein through degradation by β-secretase and γ-secretase complexes. One of the major
components of γ-secretase complex, anterior pharynx-defective-1 (APH-1), is responsible for the activity of the γ-secretase complex.
In this study, we searched for not only the most known common genetic risk factor, APOE, but also the APH-1a gene polymorphism in
AD patients in a Turkish population.
Materials and methods: In this study, 49 AD patients and 45 healthy controls were included. The genetic polymorphisms and allele
frequencies of APOE and APH-1a were investigated. Patients were evaluated for behavioral, cognitive, and functional domains by
detailed neurocognitive tests, and comparison between the above-mentioned polymorphisms and disease severity was made.
Results: Although there was an increased tendency of the APO ε4 allele in the AD group, no statistically significant difference was
detected either in APOE or APH-1a polymorphisms, not suggesting a strong susceptibility to the development of AD.
Conclusion: While searching for the pathogenesis of AD in order to develop novel diagnostic as well as therapeutic approaches, analysis
of other genes with a possible role in AD is warranted.
Key words: Alzheimer disease, APOE, APH-1A, polymorphism, biomarker

1. Introduction
Alzheimer disease (AD) is the most frequent form of dementia, characterized by progressive impairment in multiple cognitive domains. AD is a major public health issue
and places a considerable burden on society. The clinical
diagnosis of AD cannot be determined by laboratory tests.
These tests are important mainly in identifying other possible causes of dementia that must be excluded before the
diagnosis of AD is made (1). Its definite diagnosis is possible with postmortem neuropathological study (2). The following classification is used for AD: possible AD, probable
AD, and definite AD. While the first two categories are intended for clinical use, the third is intended for research
purposes (3). Early diagnosis and intervention in early
stages play important roles during the course of the disease as well as in efficacy of the treatment. The etiology of
the sporadic form of AD remains largely unknown. Recent
* Correspondence: esragunduz@outlook.com
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evidence has suggested that genetic and environmental
interactions may play a decisive role in the development
and progression of the disease (4). In terms of age of onset,
AD is classified into early-onset AD (EOAD, onset at <65
years), accounting for 1%–5% of all cases, and late-onset
AD (LOAD, onset at ≥65 years), accounting for >95% of
the patients. EOAD, also known as familial AD, is generally associated with a more rapid rate of progression and
a number of different single-gene mutations on chromosomes 21, 14, and 1. Mutations in the amyloid precursor
protein (APP), presenilin-1 (PS-1), and presenilin-2 (PS2) genes have consistently been associated with early-onset
familial AD (5). The single-gene mutations directly responsible for EOAD do not seem to be involved in LOAD.
The causes of LOAD are not completely understood, but
they are suggested to be influenced by a combination of
genetic, environmental, and lifestyle factors.
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APOE is the best-known gene to be associated with
LOAD, yet it represents only a small ratio of the genetic
factors, and probably many other genetic polymorphisms
are involved in onset of the disease (6). APOE is the major
lipoprotein within the central nervous system, where it is
synthesized by astrocytes. APOE plays an important role
in lipid metabolism (7). Injuries in the central and peripheral nervous system structures cause an increase of APOE
expression (8). The APOE protein exists in three major
isoforms: E2, E3, and E4. The APOE4 isoform, a key risk
factor for AD, is cytotoxic, and it damages the cytoskeleton, increases the production of amyloid β-peptide, and
affects mitochondrial function in neuronal cells (9).
Diagnostic accuracy is lower at early and presymptomatic stages of AD (10). It is believed that the development
of AD takes place over a long prodromal period, approximately 20 years, but this is difficult to determine because
of the absence of biomarkers that reliably determine the
onset of presymptomatic disease before the onset measurable cognitive impairments. Because intervention with
disease-modifying therapies for AD is likely to be the most
efficacious treatment method before the occurrence of
significant neurodegeneration, there is a crucial need for
biomarker-based tests that enable an accurate and early diagnosis of AD (11,12). Moreover, such tests could also provide improved monitoring for AD progression, evaluation
of new treatment strategies, and enhanced discrimination
of AD cohorts with specific subsets in clinical trials. The
ideal biomarker for AD should be reliable, noninvasive,
simple to use, and inexpensive (11).
The neuropathological hallmarks of AD are the presence of senile plaques, neurofibrillary tangles, and neuronal loss (13). Amyloid β-peptide, the major component
of senile plaques that accumulates in the brains of AD
patients, is a prooxidant and increases the formation of
reactive oxygen radicals (14). Amyloid β-peptide is derived from β-amyloid precursor protein (APP) through
sequential cleavage by the β-secretase and γ-secretase
complex (15). β-Secretase is identified as the beta-site
APP-cleaning enzyme (16) and the γ-secretase-mediated
process includes presenilin (PS), nicastrin (Nct), anteriorpharynx defective 1 (APH-1), and presenilin enhancer 2
(PEN-2) (17). APH-1, a key factor in γ-secretase activity,
forms a stable subcomplex with nicastrin and contributes
to the stabilization of the γ-secretase complex. Therefore,
variations in the APH-1 gene sequence may increase the
risk of AD by altering the γ-secretase activity. APH-1a is
the primary isoform of APH-1 in mammals (18). There are
some studies about PS and Nct of the γ-secretase complex
(19,20), but APH-1a has not been investigated thoroughly
in AD except for a few studies (21–23). Moreover, there
is no study investigating APH-1a polymorphism and AD
risk in a Turkish population.

In regard to this knowledge, we tested the hypothesis
that polymorphic alterations in APH-1a exons and
nearby intronic regions can play an important role in AD
pathogenesis. We also searched for APOE polymorphisms
and matched them with APH-1a polymorphisms to
analyze whether there is an increased risk for AD. To the
best of our knowledge, this is the first such study in the
literature in a Turkish population.
2. Materials and methods
2.1. Patients and clinical evaluation
Forty-nine patients diagnosed clinically with probable
AD according to the Neurological and Communicative
Disorders and Stroke-Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) criteria
(1) and 45 healthy controls were included in the study.
Being younger than 65 years, existence of another
neurodegenerative disease and/or a history of a
previous cerebrovascular disease, and having any other
neurological, psychiatric, or medical condition interfering
with cognition were chosen as exclusion criteria for the
case group. The study protocol was approved by the ethics
committee of the Turgut Özal University Medical Faculty.
After obtaining informed consent, detailed medical
history, neurological examination, routine blood tests,
and computed tomography and/or magnetic resonance
imaging of the brain were performed for each patient.
2.2. DNA isolation
Genomic DNAs were isolated from whole blood by
phenol-chloroform extraction assay.
2.3. DNA amplification
To study polymorphisms rs429358 T>C and rs7412
C>T, 303 bp of the APOE gene was amplified. The
primers of the APOE gene for PCR amplification
were modified from a previous report as follows:
5’-CGGGCACGGCTGTCCAAGGAG-3’(forward) and
5’-CTGGTGGAACAGGGCCGCGTG-3’ (reverse) (24).
To study polymorphism analysis of the APH-1a gene at
rs3754048 C>G, 427 bp of the genomic region was amplified
using the primers 5’-ACTGCCACCTCTGCCTCTT-3’
(forward) and 5’-CATTTCTCTCCAGGCTCCTT-3’
(reverse) as previously reported (22). The stock solution
(100 pmol/µL) was prepared from lyophilized primers
using 1X TE. The working primers for PCR amplification
were prepared as 20 pmol/µL from stock solution.
2.4. Gradient PCR
Gradient PCR was performed to determine and modify
the optimum temperature for annealing of primers for
the APOE and APH-1a genes. In the reaction Eppendorf
tubes, the total volume used in gradient PCR was 25 µL
with 10X buffer, MgCl2 (25 mM), dNTP, primers, H2O,
Taq polymerase, and DMSO. The DNA samples were
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added at the end of all procedures. Total gradient PCR mix
consisted of 10X buffer (2.5 µL), MgCl2 (2.5 µL), dNTP
(0.5 µL), forward primer (0.5 µL), reverse primer (0.5 µL),
Taq polymerase (0.2 µL), DMSO (1 µL), H2O (15.3 µL),
and DNA (2 µL) for APOE and APH-1a genes. Reaction
conditions for APOE involved an initial denaturation
of DNA at 94 °C for 5 min, followed by 38 cycles of
amplification at 94 °C for 30 s (denaturation), 71 °C for
30 s (annealing), and 72 °C for 1 min (hybridization), and
final extension at 72 °C for 5 min. Reaction conditions for
APH-1a involved the same procedures for APOE except
the annealing temperature (67 °C).
2.5. Restriction fragment length polymorphism (RFLP)
PCR products provide the sequence of polymorphism
sites for RFLP analysis. Detection of single nucleotide
polymorphism alleles was done using restriction enzymes
recognizing these regions. Enzymatic fragmentation
was performed following the control of amplification
of PCR products by agarose gel electrophoresis. After
fragmentation, 15 µL of DNA was mixed with 1 µL of 6X
loading dye and loaded into the well and run at 100 V for
45 min, followed by visualization in a UV transilluminator.
For enzymatic digestion of the APOE gene rs429358
T>C and rs7412 C>T polymorphisms, a 303-bp PCR
product was fragmented into 91-, 83-, 72-, and 48-bp
fragments using CFO1 (Hhal) enzyme (New England
Biosystems, USA). The enzyme sliced the C base from
the region of the GCGC sequence with Hhal enzyme
recognition sequence of 5’..GCG ’C…3’, 3’…C’GCG…5’.
Risk determination based on alleles was as follows:
APO E2 allele (rs429358 (T) + rs7412(T)); APO E3 allele
(rs429358 (T) + rs7412 (C) = most common allele); APO
E4 allele (rs429358(C) + rs7412(C) = risk for AD); APO
E4/E4 allele (rs429358(C;C) + rs7412(C;C) = high risk for
AD). Genotyping was as follows: E2/E2 (91 bp + 83 bp),
E3/E3 (91 bp + 48 bp), E4/E4 (72 bp + 48 bp), E2/E3 (91
bp +83 bp +48 bp), E2/E4 (91 bp + 83 bp + 72 bp + 48 bp),
E3/E4 (91 bp + 72 bp + 48 bp). Thus, polymorphic APOE
has three major isoforms: APO E2 (cys112, cys158), APO
E3 (cys112, arg158), and APO E4 (arg112, arg158).
For enzymatic digestion of the APH-1a gene rs3754048
C>G polymorphisms, a 427-bp PCR product was
fragmented into 192- and 235-bp fragments or left uncut
at 427 bp using Hae11 (Bfol) enzyme (Thermo Scientific,
USA) with Hae11 (Bfol) enzyme recognition sequence of
5’..RGCGC’Y...3’, 3’…Y’CGCGR…5’.
PCR products of APOE and APH-1a were confirmed
by 2% agarose gel electrophoresis. However, for RFLP
fragment analysis of the APOE gene, 4% agarose gel was
used.
2.6. Sequencing
In order to confirm RFLP and PCR results, the sequencing
process of some samples was conducted as follows. First
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2 µL of ExoSAP IT (GML A.G., Switzerland) was placed
into PCR tubes, and then 5 µL of PCR product was added
and tubes were placed in the thermal cycler. Reaction conditions for presequence procedure involved an initial denaturation of DNA at 37 °C for 30 min, followed by final
extension at 80 °C for 15 min and storage at 4 °C.
Eight microliters of mixture prepared for this purpose
was placed in each tube and 2 µL of DNA-treated ExoSAP was added. As a control, pGEM was used. Reaction
conditions for sequencing involved an initial denaturation of DNA at 96 °C for 1 min, followed by 25 cycles
of amplification at 96 °C for 15 s (melting), 50 °C for 15
s (annealing), and 60 °C for 4 min, and no more final
extension. PCR products were purified using Sephadex
column purification after sequencing by PCR amplification. Samples were analyzed by the Applied Biosystems
3130 genetic analyzer.
2.7. APOE PCR electrophoresis and Hhal enzyme
digestion
For evaluation of the PCR product of the searched region
for APOE, samples were run on 2% agarose gel, with
a fragment of 303 bp in length, and visualized in a UV
transilluminator (Figure 1).
In order to assess RFLP results of the investigated
region, enzyme digestion fragments were run on 4%
agarose gel, and fragments of 91 bp, 83 bp, 72 bp, and 48
bp were visualized in a UV transilluminator (Figure 2).
2.8. APH-1a PCR electrophoresis results
To evaluate PCR products of the investigated region,
samples were run on 2% agarose gel, with a fragment of
427 bp in length, and visualized in a UV transilluminator.
To assess RFLP results of the investigated region,
enzyme digestion fragments were run on 4% agarose gel,
and 427-bp, 235-bp, and 192-bp fragments were obtained
and visualized in a UV transilluminator (Figure 3).
2.9. Sequence confirmation
After detecting the presence of PCR products, certain
reference samples underwent DNA sequencing and APH1a and APOE genes were confirmed. PCR products were
purified using Sephadex column purification following
PCR amplification. Samples were analyzed by the Applied
Biosystems 3130 genetic analyzer.
2.10. Statistical analysis
SPSS 11.5 was used for the statistical analysis of the data.
The Kolmogorov–Smirnov test was used to detect the
accuracy of the normal distribution of continuous and
discrete variables. The descriptive statistical methods
applied for the continuous and discrete variables were
standard deviation, mean, and median, while case
numbers and percentages were applied for categorical
variables. Statistical significances of mean values among
groups were tested with Student’s t-test. Differences
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Figure 1. Agarose gel image of APOE PCR amplification products from gradient PCR.

between groups based on the median values were tested
with the Mann–Whitney U test. Pearson’s chi-square test,
Fisher’s exact test, and likelihood ratio tests were used to
compare categorical variables. The relationship between
the continuous and discrete variables among themselves
was tested with the Spearman’s correlation test. Odds
ratio and confidence intervals (95% confidence interval)
were examined to assess the susceptibility of APH-1a and
APOE genotypes and alleles to the risk of AD. P < 0.05 was
considered significant.
3. Results
3.1. Demographic data and comorbid conditions in
patient and control groups
A total of 49 patients diagnosed with AD (30 women and
19 men; average age of 78.5 ± 6.8 years) and 49 healthy
participants (27 women and 18 men; average age of 71.9

Figure 3. Agarose gel image of APH-1a RFLP products.

± 8.7 years) were examined. Fifteen (30.6%) patients had
a family history of AD. Members of the control group had
no family history of AD.
3.2. Allele distributions of APOE and APH-1a genes
APOE allele distribution of patient and control groups
is shown in Table 1, while APH-1a allele distribution is
shown in Table 2. The most frequent allelic distribution
was ε3/ε3 in both groups (57.1% and 64.4%, respectively).
The frequency of carrying at least one ε4 allele was found
to be 32.7% in the patient group and 17.8% in the control
group (P > 0.05). The ε2 allele frequency distribution in
the patient group was 6.1% and it was 10% in the control
group. The ε3 allele frequency distribution in the patient
group was 75.5% and it was 80% in the control group (P
> 0.05). The ε4 allele frequency distribution in the patient
group was 18.4% and it was 10% in the control group (P >

Figure 2. Agarose gel image of APOE RFLP products.

1101

ACAR ÇİNLETİ et al. / Turk J Med Sci
Table 1. Distribution of APOE polymorphisms and allele frequencies in patient and
control groups.
Variables

Control

AD

P-value

ε2/ε2

0 (0.0%)

1 (2.0%)

-

ε3/ε3

29 (64.4%)

28 (57.1%)

1.000

ε4/ε4

1 (2.2%)

2 (4.1%)

-

4 (8.2%)

0.385

APO E genotype

ε2/ε3

8 (17.8%)

ε2/ε4

1 (2.2%)

0 (0.0%)

-

ε3/ε4

6 (13.3%)

14 (28.6%)

1.000

ε4 allele (+)

37 (82.2%)

33 (67.3%)

-

ε4 allele (-)

8 (17.8%)

16 (32.7%)

0.098

ε2

9 (10.0%)

6 (6.1%)

-

ε3

72 (80.0%)

74 (75.5%)

0.433

ε4

9 (10.0%)

18 (18.4%)

0.099

APO E genotype

APO E Allele Frequency

Table 2. APH-1a polymorphisms: genotypes and allele distribution in patient and
control groups.
Variables

Control

AD

P-value

CC

20 (44.4%)

20 (43.5%)

-

GC

25 (55.6%)

25 (54.3%)

1.000

GG

0 (0.0%)

1 (2.2%)

1.000

C

65 (72.2%)

65 (70.7%)

-

G

25 (27.8%)

27 (29.3%)

0.815

APH-1a genotype

APH-1a allele frequency

0.05). No statistically significant difference was observed
between the patient and control groups in terms of prevalence of ε4 allele, but a tendency was detected between ε4
allele presence and AD (P > 0.05) (Table 1).
The effects of vascular risk factors (diabetes, hypertension, and hyperlipidemia) were investigated. Diabetic patients were 26.5% of the AD group and 26.7% of the control group. Hyperlipidemia was detected in 22.4% of the
AD group and 35.6% of the control group. Hypertension
was present in 73.5% of the AD group and 73.3% of the
control group. Almost 30% of the AD group had a family
history of AD.

1102

Allele and genotype frequencies of the APH-1a gene in
patient and control groups are shown in Table 2. There was
no statistically significant difference for APH-1a CC, GC,
or GG genotype prevalence between patients and control
subjects (P > 0.05). When allele frequencies were studied,
allele frequency of the G allele was 29.3% in the AD group
and 27.8% in the control group, whereas allele frequency
of the C allele was 70.7% in the AD group and 72.2% in the
control group. This did not cause a statistically significant
difference (P > 0.05) (Table 2).
Among subjects with APH-1a GG or GC, 30.8% of the
patient group and 12% of the control group were found to
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be a carrier of at least one ε4 allele of APOE. Additionally,
69.2% of the AD group was G allele (+) but ε4 (-), whereas
88% of the control group was G allele (+) but ε4 (-). The
relationship between APH-1a and APOE alleles was not
statistically significant (P > 0.05) (Table 3).
There was no significant relationship between APOE
ε4 allele and APH-1a G allele with family history of AD (P
> 0.05) (Table 4).
4. Discussion
Identifying individuals at risk of AD, managing controllable
risk factors, and ensuring early diagnosis and treatment
have gained more importance in recent years (25). The
best-known genetic risk factor is the ε4 allele of the APOE
gene (26). The mechanisms of the synthesis of APOE in
the brain are still not completely known. Many studies
performed on AD patients have shown that being a carrier
of the ε4 allele of APOE not only increases the risk of AD
but also expedites the age of onset of the disease (27). The
number, diameter, and intensity of amyloid β plaques are
strongly related to the APOE genotype (28).
On the other hand, although the APOE ε4 allele
is a potent risk factor for AD, most APOE ε4 carriers
do not develop dementia, and about one-half of AD is
not APOE ε4-associated while the presence of the ε4
allele has a limited predictive value in asymptomatic
persons (29). In the literature, there is a consensus
that APOE genotyping should not be used for diagnostic

testing (30). This suggests that there are other genetic and
environmental factors playing a role in the development
of dementia. In our study, there was no patient carrying
the ε2/ε4 genotype. There was no person carrying the ε2/
ε2 genotype in the control group. The ε3/ε3 genotype is
the most frequent genotype in both groups. The frequency
of being a carrier of at least one ε4 allele was 32.7% in the
patient group, while it was 17.8% in the control group.
Although these data suggest the increase of frequency
of ε4 allele in the AD group, it did not reach statistical
significance. In previous studies, it was demonstrated that
the ε3 allele is the most frequently seen genotype in the
population, as we confirmed with our study. Two studies
in Turkey declared that ε2 allele frequency was higher in
the patient group, contradictory to our data (31,32).
Studies have demonstrated that nicastrin, APH-1a,
APH-1b, and PEN-2 genes interact with presenilins and
are required for the intramembrane proteolysis of APP
and other γ-secretase substrates (32–35). Small RNA
prevents the formation of multimeric complexes of APH1a and APH-1b, as well as decreasing the production of
amyloid β-peptide (17). Therefore, sequence variations
in the APH-1 gene interfere with γ-secretase activity and
have a role in determining the risk of sporadic AD. In
this study, we tested this hypothesis by analyzing APH-1a
for the presence of polymorphisms in a Turkish sample
of sporadic AD cases and controls. As shown in Table 3,
there was no statistically significant difference in genotype

Table 3. Distribution and matching of APH-1a G allele and APOE ε4 allele within the
groups.
APH-1a

Variables

G allele (+)

G allele (-)

Control

P-value
0.435

ε4 (+)

3 (12.0%)

5 (25.0%)

ε4 (-)

22 (88.0%)

15 (75.0%)

AD

0.762

ε4 (+)

8 (30.8%)

7 (35.0%)

ε4 (-)

18 (69.2%)

13 (65.0%)

Table 4. Relationship of APOE and APH-1a with family history of AD.
Comorbid conditions
GG+GC
Family history
of AD

APH-1a

APOE

CC

P-value

Positive

15 (53.6%)

13 (46.4%)

Negative

9 (60%)

6 (40%)

E4 allele
P = 0.686

Other alleles

P-value

7 (23.3%)

23 (76.7)

7 (46.7%)

8 (53.3)

P = 0.172
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or allele frequencies of the APH-1a G allele in AD subjects
and controls. Our study elucidates how polymorphisms
in APH-1a and APOE genes are associated with sporadic
AD. The analysis of genotypes and allele frequencies of the
APH-1a and APOE genes did not reveal any statistically
significant differences among AD cases and controls.
In a previous study investigating the sequence variations
in the promoter area of the APH-1a gene, only the 980C⁄G
(rs3754048) single nucleotide polymorphism was found to
be associated with AD (36). Regarding this information, we
studied 980C⁄G (rs3754048) polymorphism of the APH-1a
gene together with rs429358 and rs7412 polymorphisms of
the APOE gene.
It was found that 30.8% of the patient group and 12%
of the control group had the concurrence of at least one G
allele of APH-1a and at least one ε4 allele of APOE. This did
not reach statistical significant difference. In their study,
Wang et al. revealed that the GG genotype and G allele
frequency of the -980 C/G (rs3754048) polymorphism was
increased in the patient group compared with the control
group. At the same time, the frequency of APOE ε4 was
increased in carriers of the G allele of APH-1a. Wang et
al. stated that there is a relationship between the -980 C/G
polymorphism of APH-1a and sporadic AD, possibly due
to the synergistic interaction between the G allele and
APO ε4 (21). Qin et al. reported that the presence of the
G allele was higher in the patient group, and therefore
they declared that APH-1a polymorphism leads to an
increased risk of AD. The possible underlying mechanism
is the G allele, which has a higher transcriptional activity

causing overexpression of APH-1a (22). In another study
conducted by Poli et al., it was concluded that APH-1a
and APH-1b did not increase the risk of AD in an Italian
population and the disease risk was not connected to
the presence of APOE ε4 (23). A study performed by the
same group revealed that there is a potential relationship
between APH-1b C + 651 T>G polymorphism and the
APOE ε4 allele in AD and both gene polymorphisms
relatively increase the risk of AD. According to these
findings, AD risk increases 3.3-fold in patients positive for
APOE ε4 but negative for APH-1b G allele, whereas the
risk of AD increases 28.6-fold in patients carrying both
alleles. Contrarily, carrying only APH-1b did not cause an
increase in the risk of AD (36).
In summary, our study points out that sequence
variations in APH-1a and APOE do not affect the risk of
sporadic AD in the Turkish population. In addition, our
results demonstrate that there is no genetic interaction
between APOE and APH-1a alleles. This is the first study
to investigate the relationship between APH-1a gene
polymorphisms and AD risk in Turkish patients. This
study could provide insight for other studies that might
be examining the hypothesis in sporadic AD in very large
populations in the future.
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